Back to search

Peptide record

TPDB40764

BR-C Anticancer standard
25 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB40764
BR-C
Anticancer
Cancer-related peptides
CancerPPD 2.0 dbACP
standard
No
A 25-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0 and dbACP, with an available 3D structural model.
C-terminal: Cyclized N-terminal: Cyclized
Sequence
CKLKNFAKGVAQSLLNKASKLSGQC
Physicochemical Analysis
C114H198N34O33S2
RDEHIMPTWY
K
2637.15
10.39
5
0
9
+5
3.07
-0.164
86.00
Mammalian: 1.2 hour Yeast: >20 hour E.coli: >10 hour
125
4.74
9
Residue Composition
number
3
A
0
R
2
N
0
D
2
C
0
E
2
Q
2
G
0
H
0
I
4
L
5
K
0
M
1
F
0
P
3
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 3 R: 0 N: 2 D: 0 C: 2 E: 0 Q: 2 G: 2 H: 0 I: 0 L: 4 K: 5 M: 0 F: 1 P: 0 S: 3 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
25
C114H198N34O33S2
2637.15
10.39
+5
3.07
-0.164
Cyclized
L
Cyclic
Cyclized
Antimicrobial
Synthetic
Evidence Records 2 records
Evidence 1 Activity

Activity

IC50
IC50 = 45.72 µg/ml
Anticancer
45.72 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2017

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 75.44 µg/ml
Anticancer
75.44 µg/mL

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2017